United States:
BPCIA Questions Continue To Arise For Biosimilar Applicants
17 August 2017
Kramer Levin Naftalis & Frankel LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Intellectual Property partner Gregory B. Sephton, special
counsel Christine Willgoos and associate John P. Dillon's
article "BPCIA Questions Continue To Arise For Biosimilar
Applicants" appeared in Law360 on July 24, 2017. The
article examines the Supreme Court's decision in Sandoz
Inc. v. Amgen Inc., the first case under the Biologics Price
Competition and Innovation Act of 2009.
Read the full article here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.